

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

4

Complete if Known

Application Number	10/724,397; Confirmation 8892
Filing Date	12/1/2003
First Named Inventor	Goldenberg
Art Unit	1616
Examiner Name	Jagadishwar Samala
Attorney Docket Number	330687

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/JS/	3	CASEY, J. L., et al., "Clearance of yttrium-90-labeled anti-tumour antibodies with antibodies raised against the 12N4 DOTA macrocycle" British Journal of Cancer (1998) 78(10), 1307-1312 XP-000986994	
	4	ROWLINSON-BUSZA, Gail, et al., "90Y-Labeled Antibody Uptake by Human Tumor Xenografts and The Effect of Systemic Administration of EDTA" Int. J. Radiation Oncology Biol. Phys., Vol. 28, No. 5, pp. 1257-1265 (1994)	
	5	DENARDO, Sally J., et al., "Yttrium-90/Indium-111-DOTA-Peptide-Chimeric L6: Pharmacokinetics, Dosimetry and Initial Results in Patients with Incurable Breast Cancer" Anticancer Research 17: 1735-1744 (1997)	
	6	ADAMS, G. P., et al., "Delivery of the α -Emitting Radioisotope Bismuth-213 to Solid tumors via Single-Chain Fv and Diabody Molecules" Nuclear Medicine & Biology, Vol. 27, pp. 339-346, 2000	
	7	BEHR, THOMAS M., et al., "High-Linear Energy Transfer (LET) α versus Low-LET β Emitters in Radioimmunotherapy of Solid Tumors: Therapeutic Efficacy and Dose-limiting Toxicity of 213Bi-versus 90Y-labeled CO17-1A Fab' Fragments in a Human Colonic Cancer Model" Cancer Research 59, 2635-2643, June 1, 1999	
	8	GOVINDAN, SERENGULAM V., et al., "90 Yttrium-Labeled Complementarity-Determining-Region-Grafted Monoclonal Antibodies for Radioimmunotherapy: Radiolabeling and Animal Biodistribution Studies" Bioconjugate Chem. 1998, 9, 773-782	
	9	WONG, JEFFREY Y. C., et al., "A Phase I Radioimmunotherapy Trial Evaluating 90 Yttrium-labeled Anti-Carcinoembryonic antigen (CEA) Chimeric T84.66 in Patients with Metastatic CEA-producing Malignancies" Clinical Cancer Research, Vol. 6, 3855-3863, October 2000	
	10	DAVIS, ILA A. et al., "Radioimmunotherapy Using Vascular Targeted 213Bi: The Role of Tumor Necrosis Factor α in the Development of Pulmonary Fibrosis" Clinical Cancer Research 3160s Vol. 5, 3160s-3164s, October (1999) (Suppl.)	
	11	WATANABE, NAOYUKI, et al., "CaNa2 EDTA for Improvement of Radioimmunodetection and Radioimmunotherapy with 111In and 90Y-DTPA-Anti-CEA Mabs in Nude Mice Bearing Human Colorectal Cancer" The Journal of Nuclear Medicine, Vol. 41, No. 2, February 2000 pgs 338-344	
↓	12	JONES, SHAUN B. et al., "Evaluation of Dithiol Chelating Agents as Potential Adjuvants for Anti-IL-2 Receptor Lead or Bismuth Alpha Radioimmunotherapy" Nuclear Medicine & Biology, Vol. 23, pp. 105-113, 1998	
/JS/	13	GOODWIN, D. A., et al., "Monoclonal antibody hapten radiopharmaceutical delivery" Nuclear Medicine Communications 7, 569-580 (1986)	

Examiner
Signature

/Jagadishwar Samala/ (03/19/2007)

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

4

Complete if Known

Application Number	10/724,397; Confirmation 8892
Filing Date	12/1/2003
First Named Inventor	Goldenberg
Art Unit	1616
Examiner Name	Jagadishwar Samala
Attorney Docket Number	330687

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/JS/	14	JUWEID, MALIK E., et al., "Phase III Trial of 131I-MN-14 F(ab)2 Anti-Carcinoembryonic Antigen Monoclonal Antibody in the Treatment of Patients with Metastatic Medullary Thyroid Carcinoma" Cancer April 15 (1999), Vol. 85, No. 8, pp. 1828-1842	
	15	KARACAY, et al., "Development of a Streptavidin-Anti-Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pre-targeting Method for Radioimmunotherapy of Colorectal Cancer. Reagent Development" Bioconjugate Chem. 1997, 8, 585-594	
	16	BEHR, THOMAS M., et al., "Phase III Clinical Radioimmunotherapy with an Iodine-131-Labeled Anti-Carcinoembryonic antigen Murine Monoclonal Antibody IgG" The Journal of Nuclear Medicine, Vol. 38, No. 6, June 1997, pgs. 858-870	
	17	ULLEN, ANDERS, et al., "Use of Anticytokeratin Monoclonal Anti-Idiotypic Antibodies to Improve Tumor: Nontumor Ratio in Experimental Radioimmunolocalization" Cancer Research (Suppl.) 55, 5868s-5873s, December 1 (1995)	
	18	ONG, GAIK LIN, et al., "The fate of antibodies and their radiolabels bound to tumor cells in vitro: the effect of cross-linking at the cell surface and of anti-idiotypic antibodies" Cancer Immunol Immunotherapy (1994) 39: 325-331	
	19	SHARKEY, ROBERT M., et al., "Clinical Evaluation of Tumor Targeting with a High-Affinity, Anticarcinoembryonic-Antigen-Specific, Murine Monoclonal Antibody, MN-14" Cancer March 15 (1993), Vol. 71, No. 6 pgs. 2082-2846	
	20	PIMM, M. V., et al., "Influence of syngeneic monoclonal anti-idiotypic antibodies to murine Monoclonal antibodies against tumour-associated antigens on the biodistribution of their target antibodies and their fragments" J Cancer Res Clinical Oncology (1993) 119:408-414 pgs 408-414	
	21	SCHIELE, J., et al., "The effect of unlabelled monoclonal antibody (mAb) on the biodistribution of 131I-anti-idiotypic mAb in murine B cell lymphoma" Radiotherapy and Oncology, 24 (1992) 169-176 pgs. 169-176	
	22	SHARKEY, ROBERT M., et al., "Enhanced Clearance of Radiolabeled Murine Monoclonal Antibody by a Syngeneic Anti-Idiotypic Antibody in Tumor-Bearing Nude Mice" Int. J. Cancer 51, 266-276 (1992)	
	23	GOLDENBERG, DAVID M., et al., "Targeting, Dosimetry, and Radioimmunotherapy of B-Cell Lymphomas with Iodine-131-Labeled LL2 Monoclonal Antibody" Journal of Clinical Oncology, Vol. 9, No. 4 (April 1991), pp. 548-564	
/JS/	24	STEWART, J. SIMON W., et al., "Clearance of 131I-labeled Murine Monoclonal Antibody from Patients' Blood by Intravenous Human Anti-Murine Immunoglobulin Antibody" Cancer Research 50, 563-567, February 1, 1990	

Examiner
Signature

/Jagadishwar Samala/ (10/19/2007)

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 4

Complete if Known

Application Number	10/724,397; Confirmation 8892
Filing Date	12/1/2003
First Named Inventor	Goldenberg
Art Unit	1616
Examiner Name	Jagadishwar Samala
Attorney Docket Number	330687

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/JS/	25	BLUMENTHAL, RASALYN D. et al., "Reduction by Anti-Antibody Administration of the Radiotoxicity Associated with 131I-Labeled Antibody to Carcinoembryonic Antigen in Cancer Radioimmunotherapy" Journal of the National Cancer Institute Vol. 81, No. 3, February 1, 1989	
/JS/	26	PIMM, M. V., et al., "The Influence of Syngeneic Anti-Idiotypic Antibody on the Biodistribution of an anti-tumour monoclonal Antibody in Balb/c Mice" Int. J. Cancer: 43, 147-151 (1989)	
/JS/	27	SHARKEY, ROBERT M., et al., "Factors Influencing Anti-Antibody Enhancement of Tumor Targeting with Antibodies in Hamsters with Human Colonic Tumor Xenografts" Cancer Research 48, 2005-2009, April 15, 1988	
/JS/	28	GOLDENBERG, DAVID M., et al., "Anti-Antibody Enhancement of Iodine-131 Anti-CEA Radioimmunodetection in Experimental and Clinical Studies" The Journal of Nuclear Medicine, Volume 28, Number 10, October 1987, pp 1604-1610	
/JS/	29	SHARKEY, Robert M., et al. "Clinical Evaluation of Tumor Targeting with a High-Affinity, Anticarcinoembryonic-Antigen-Specific, Murine Monoclonal Antibody, MN-14" Cancer March 15, 1993, Volume 71, No. 6, pp 2082-2096	

Examiner
Signature

/Jagadishwar Samala/ (03/19/2007)

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IDS 01/04/2007

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10724397
Filing Date	2003-12-01
First Named Inventor	Goldenberg
Art Unit	1618
Examiner Name	Jagadishwar Rao Samala
Attorney Docket Number	330687

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10724397
Filing Date	2003-12-01
First Named Inventor	Goldenberg
Art Unit	1618
Examiner Name	Jagadishwar Rao Samala
Attorney Docket Number	330687

JS	1	BEHR, THOMAS, et al., "High-Linear Energy Transfer (LET) a versus Low-LET B Emitters in Radioimmunotherapy of Solid Tumors: Therapeutic Efficacy and Dose-limiting Toxicity of 213Bi-versus 90Y-labeled CO17-1A Fab' Fragments in a Human Colonic Cancer Model ¹ " Cancer Research 59, 2635-2643, June 1, 1999, XP-000982262	<input type="checkbox"/>
JS	2	GOVINDAN, SERENGULAM V., et al., "90Yttrium-Labeled Complementarity-Determining-Region-Grafted Monoclonal Antibodies for Radioimmunotherapy: Radiolabeling and Animal Biodistribution Studies" Bioconjugate Chem., vol. 9, No. 6, 1998, 773-782 XP-0009B2306	<input type="checkbox"/>
JS	3	CASEY, J. L., et al., "Clearance of yttrium-90-labelled anti-tumour antibodies with antibodies raised against the 12N4 DOTA Macrocyclic" British Journal of Cancer (1998) 78(10), 1307-1312 XP-000986994	<input type="checkbox"/>
JS	4	ROWLINSON-BUSZ, GAIL, et al., "90Y-Labeled Antibody Uptake by Human Tumor Xenografts and The Effect of Systemic Administration of EDTA" Int. J. Radiation Oncology Biol. Phys., Vol. 28, No. 5, pp. 1257-1265, 1994 XP-000986989	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Jagadishwar Samala/ (03/02/2007)	Date Considered
--------------------	-----------------------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10724397
Filing Date	2003-12-01
First Named Inventor	Goldenberg
Art Unit	1618
Examiner Name	Jagadishwar Rao Samala
Attorney Docket Number	330687

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Richard A. Nakashima/	Date (YYYY-MM-DD)	2007-01-03
Name/Print	Richard A. Nakashima	Registration Number	42,023

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.